Lorcaserin

Drug Profile

Lorcaserin

Alternative Names: APD 356; Belviq; Belviq XR; Lorcaserin controlled-release; Lorcaserin extended-release; Lorcaserin HCl; Lorcaserin hydrochloride; Venespri

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Eisai Inc; Ildong Pharmaceutical
  • Class Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Obesity
  • Discontinued Smoking withdrawal

Most Recent Events

  • 04 Jan 2017 Eisai acquires lorcaserin from Arena Pharmaceuticals
  • 20 Dec 2016 Registered for Obesity in Brazil (PO)
  • 03 Oct 2016 Launched for Obesity in USA (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top